Comparison of reference Infliximab and a Biosimilar (CT-P13) in Crohn's Disease (CME/CE)
(MedPage Today) -- Analysis of real-world data show that CT-P13 is equivalent to infliximab in infliximab-naive patients with CD (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 12, 2018 Category: Gastroenterology Source Type: news
Biosimilar CT-P13 Matches Infliximab for Crohn's Disease Biosimilar CT-P13 Matches Infliximab for Crohn's Disease
Crohn ' s disease was effectively and safely treated either with infliximab or with the biosimilar CT-P13, according to an observational cohort study of more than 5000 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Reference Infliximab, Biosimilar Equivalent for Crohn's Disease
TUESDAY, Dec. 11, 2018 -- CT-P13, which is a biosimilar of the reference product (RP) infliximab, has equivalent effectiveness for infliximab-naive patients with Crohn ' s disease (CD), according to a study published online Dec. 11 in the Annals of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2018 Category: Pharmaceuticals Source Type: news
Biosimilar CT-P13 Matches Infliximab in Crohn ’s Disease
(MedPage Today) -- With comparable safety and efficacy, drug choice may come down to cost (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 11, 2018 Category: Gastroenterology Source Type: news
Novartis launches third-to-market Remicade copy in Germany
Novartis launched a copy of Johnson& Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. (Source: Reuters: Health)
Source: Reuters: Health - November 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Johnson & Johnson edges past profit estimates, lifts outlook
Johnson& Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Johnson & Johnson profit beats, lifts forecast on cancer drug demand
Johnson& Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Infliximab Biosimilar vs Infliximab Reference Product for RA Infliximab Biosimilar vs Infliximab Reference Product for RA
How does this infliximab biosimilar and the reference product compare in terms of efficacy, safety, pharmacokinetics, and immunogenicity?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb
WEDNESDAY, Sept. 5, 2018 -- Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb, according to a research letter published in the Sept. 4 issue of the Journal of the American Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2018 Category: Pharmaceuticals Source Type: news
Is Infliximab Associated with Infection Risk in Psoriasis?
(MedPage Today) -- New study suggests it is (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 12, 2018 Category: Rheumatology Source Type: news
Study Supports Safety of Infliximab in Pregnancy Study Supports Safety of Infliximab in Pregnancy
New registry data should help reassure women with Crohn ' s disease (CD) who need to continue infliximab during pregnancy that it won ' t harm their baby.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
High Infliximab Levels Offer Safe Inflammation Control in IBD (CME/CE)
(MedPage Today) -- No increase in infections with trough levels>7 ug/mL (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 17, 2018 Category: Gastroenterology Source Type: news
J & J beats quarterly expectations on drug sales surge, shares jump
Johnson& Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade, and its shares rose more than 4 percent. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Johnson & Johnson profit beat fueled by strength in pharma business
Johnson& Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Inflectra (Infliximab-Dyyb Intravenous Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news
